this post was submitted on 18 Mar 2026
17 points (100.0% liked)

Science

15838 readers
49 users here now

Studies, research findings, and interesting tidbits from the ever-expanding scientific world.

Subcommunities on Beehaw:


Be sure to also check out these other Fediverse science communities:


This community's icon was made by Aaron Schneider, under the CC-BY-NC-SA 4.0 license.

founded 4 years ago
MODERATORS
 

Summary:

A redesigned cancer immunotherapy is showing striking early results after decades of disappointment with similar drugs. Researchers engineered a more powerful CD40 agonist antibody and changed how it’s delivered—injecting it directly into tumors instead of into the bloodstream. In a small clinical trial of 12 patients with metastatic cancers, six saw their tumors shrink and two experienced complete remission.

top 5 comments
sorted by: hot top controversial new old
[–] Powderhorn@beehaw.org 16 points 1 day ago (1 children)

... in two out of 12 people. This is certainly a promising breakthrough, and a 17% chance of complete remission is a hell of a lot better than zero. It will be interesting to see the results of the Phase 2 trial.

[–] Hirom@beehaw.org 1 points 7 hours ago* (last edited 7 hours ago) (1 children)

For approval, a new treatment has to show it's better than already approved treatments. Not better than nothing.

This appear to target difficult to treat cancer so any result is encouraging, especially in a clinical trial.

[–] Powderhorn@beehaw.org 3 points 7 hours ago

Sure, but chemo has such absurd side effects that coming up with a new approach is going to be great even if it's maybe less effective.

[–] neutronbumblebee@mander.xyz 6 points 1 day ago (1 children)

This is also a good example for the crowd who don't think progress is being made. Curing mice of cancer eventually flows though to human lives saved.

[–] realitista@lemmus.org 4 points 1 day ago

We've made huge progress in cancer treatment in my lifetime. I hope to see it more or less cured in the time I have left.